MAP1LC3A and gastric cancer: In the present study, we observed that gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, activated autophagy in the gastric cancer cells, as indicated by LC3-positive puncta and increased the levels of the autophagosome-bound form of LC3, LC3 II (Fig. 3A and B).